New guidance outlines use of first immunotherapy for children newly diagnosed with type 1 diabetes
For the first time, children ages 8 to 17 who are newly diagnosed with type 1 diabetes have access to an approved treatment that targets the underlying autoimmune disease, rather than solely managing blood sugar levels with insulin.
<p>For the first time, children ages 8 to 17 who are newly diagnosed with type 1 diabetes have access to an approved treatment that targets the underlying autoimmune disease, rather than solely managing blood sugar levels with insulin.</p>